Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
OncoSil FDA HDE Application Reaches Final Review as TRIPP-FFX Hits Endpoints
OncoSil's FDA HDE for distal cholangiocarcinoma advances to final review as TRIPP-FFX hits endpoints in pancreatic cancer; ASX: OSL.
Latest Stories — SECTOR DESK
LTR Pharma Signs Binding US Telehealth Term Sheet For ROXUS
LTR Pharma signs binding US telehealth term sheet with Shed Holdings for ROXUS via Mavrox; Definitive Agreements in 60 days to kickstart US commercialization.
EBR Systems Completes Institutional Components of Capital Raising
EBR Systems secures $106.4m in institutional raise at $0.38/CDI; retail offer opens June 11; second tranche awaits shareholder approval.
Biome Australia to Commence Domestic Production of Activated Probiotics Range
Biome Australia moves to onshore production of Activated Probiotics, targeting margin rise from 61% toward 65%+ as inventory and lead times shrink.
Vitrafy Life Sciences Strikes US Partnership to Promote Cryopreservation Ecosystem for Red Blood Cells
Vitrafy inks US Vitalant pact to deploy next-gen cryopreservation for red blood cells as glycerol tech ends by 2027; signals early market traction.
Austco Healthcare Projects Strong FY26 Growth Driven by US Rollout and New Contracts
Austco Healthcare forecasts FY26 revenue A$90-95m and NPAT up 52-58%, led by US Pulse Mobile rollout to 180 hospitals and new contracts.
Memphasys Signs Distribution Deal for Felix Fertility Device into IVF Clinics throughout Vietnam
Memphasys inks $530,000 Vietnam deal to distribute Felix fertility device through TMSC Vietnam, marking first SE Asia partnership and rapid IVF market expansion.
Emyria Poised for Operational Boost as TGA Broadens Psych-Therapy Prescriber Access
Emyria is set to accelerate recruitment as TGA broadens Authorised Prescriber roles for psychedelic therapy, boosting Empax network expansion into H2 2026.
Recce Pharmaceuticals Signs Distribution Agreement for R327 Diabetic Foot Gel across MENA
Recce inks 10-year exclusive MENA licensing deal for R327G diabetic foot gel; upfront fees up to $5m, 30% net sales, Phase III data eyed for year-end approval.
EMVision Medical Devices De-Risks Rural Stroke Use Cases with Aeromedical Study
EMVision de-risks rural stroke use with aeromedical feasibility study; First Responder Brain Scanner unaffected by flight, cash reserves of $18.4m.
Noxopharm Studies Confirm Cancer-Fighting Potential of Sofra Platform
Noxopharm data show Sofra's TLR8-boosting oligonucleotides could amplify cancer immunotherapy; US patent backing strengthens breakthrough potential.
NeuroScientific Biopharmaceuticals Reports Positive Results from StemSmart Crohn’s Trial
NeuroScientific reports on StemSmart Crohn’s trial: 80% clinical response in five patients; safe, paving Phase 2 and a potential entry to a US$13.8B market.